Please wait while the formulary information is being retrieved.
VINORELBINE TARTRATE (VINORELBINE TARTRATE)
- Non-small cell lung cancer
10 mg/mL intravenous solution
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
50 mg/5 mL intravenous solution
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
vinorelbine 10 mg/mL intravenous solution
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
vinorelbine 50 mg/5 mL intravenous solution
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
10 mg/mL intravenous solution
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
50 mg/5 mL intravenous solution
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
Metastatic breast carcinoma
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route on days 1 and 8 of cycle and repeat every 3 weeks
- Inject 30 mg/m2 over 6-10 minute(s) by intravenous route on days 1 and 8 of cycle and repeat every 3 weeks
- Inject 35 mg/m2 over 6-10 minute(s) by intravenous route on days 1 and 8 of cycle and repeat every 3 weeks
- Infuse 35 mg/m2 over 6-10 minute(s) by intravenous route on days 1 and 8 of cycle and repeat every 3 weeks
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Inject 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Inject 25 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Infuse 25 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
Non-small cell lung cancer
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Inject 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Infuse 25 mg/m2 over 6-10 minute(s) by intravenous route on days 1, 8, 15 and 21 of a 28 day treatment cycle
- Inject 25 mg/m2 over 6-10 minute(s) by intravenous route on days 1, 8, 15 and 21 of a 28 day treatment cycle
Small cell lung carcinoma
- Infuse 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Inject 30 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Inject 25 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- Infuse 25 mg/m2 over 6-10 minute(s) by intravenous route every 7 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- itraconazole
- ketoconazole
- Noxafil
- Onmel
- posaconazole
- Sporanox
- Sporanox Pulsepak
- Versacloz
- Vfend
- Vfend Iv
- voriconazole
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Anemia
- Gastrointestinal obstruction
- Gastrointestinal perforation
- Ileus
- Infection
- Interstitial pneumonitis
- Intestinal ischemic necrosis
- Neutropenic disorder
- Peripheral neuropathy
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Hepatic metastases
- Severe hepatic disease
VINORELBINE TARTRATE (VINORELBINE TARTRATE)
- Non-small cell lung cancer
- Anemia
- Hyperbilirubinemia
- Hypesthesia
- Increased aspartate transaminase
- Injection site sequelae
- Leukopenia
- Neutropenic disorder
- Paresthesia
- Peripheral neuropathy
- Phlebitis after infusion
- Alopecia
- Constipation
- Fatigue
- General weakness
- Nausea
More Frequent
Severe
Less Severe
- Chest pain
- Ototoxicity
- Stomatitis
- Anorexia
- Arthralgias
- Diarrhea
- Jaw pain
- Myalgias
- Severe nausea
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Acute respiratory distress syndrome
- Angioedema
- Bronchospastic pulmonary disease
- Deep venous thrombosis
- Dyspnea
- Esophagitis
- Extravasation injury
- Gastrointestinal obstruction
- Gastrointestinal perforation
- Hemorrhagic cystitis
- Hypertension
- Hyponatremia
- Hypotension
- Interstitial pneumonitis
- Intestinal ischemic necrosis
- Palmar-plantar erythrodysesthesia
- Pancreatitis
- Paralytic ileus
- Peripheral motor neuropathy
- Pneumonia
- Pulmonary edema
- Pulmonary thromboembolism
- Radiation recall syndrome
- SIADH syndrome
- Tachycardia
- Thrombocytopenic disorder
Less Severe
- Acute abdominal pain
- Back pain
- Dysphagia
- Flushing
- Gait abnormality
- Hyporeflexia
- Muscle weakness
- Pruritus of skin
- Skin rash
- Urticaria
- Vasodilation of blood vessels
Contraindicated
None
Severe Precaution
Vinorelbine (IV)
Higher incidence of Grade3-4 neutropenia or anemia, dyspnea, hypoxia. Risk of motor and cranial neuropathy. Lack of tumor response in treating CNS tumors or neuroblastoma.
- 1 Day – 18 Years
- Higher incidence of Grade3-4 neutropenia or anemia, dyspnea, hypoxia. Risk of motor and cranial neuropathy. Lack of tumor response in treating CNS tumors or neuroblastoma.
Management or Monitoring Precaution
None
Vinorelbine
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Vinorelbine
Insuff. Data avail;Potential severe toxicity including bone marrow depression.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff. Data avail;Potential severe toxicity including bone marrow depression. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication must be given only by injection into a vein (intravenously-IV) by a trained healthcare professional. Deaths have occurred with medications similar to vinorelbine that were injected into the spine. Vinorelbine can lower your blood cell counts (bone marrow suppression) and lower your ability to fight an infection.<br /><br />Your doctor will follow your blood counts closely. Tell your doctor right away if you develop any signs of an infection such as fever, chills, or persistent sore throat. If this medication accidentally leaks out of your vein into surrounding tissue, the skin and/or muscle may be severely damaged. Tell your doctor right away if you have pain, redness, swelling, or discoloration at the injection site.
| Non-small cell lung cancer | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| 0-9 | A-Z |
|---|---|
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
Formulary Reference Tool